Boston Life Sciences, Inc.

Agreement signed with U.S. FDA for new SPA for phase III program for Altropane

Published in Medical Imaging Week, September 17th, 2005

Boston Life Sciences, Inc., (BLSI) announced that, at the request of the company, the U.S. Food and Drug Administration (FDA) granted a new Special Protocol Assessment (SPA) for Altropane, the company's molecular imaging agent that is being developed to aid in the differentiation of Parkinsonian Syndrome (PS) tremor from non-Parkinsonian tremor.

Under the terms of this agreement with the FDA, the company may conduct two smaller phase III trials, POET-1 and POET-2, rather than one large phase III trial without sacrificing its SPA status and will be permitted to include all subjects currently enrolled in the existing phase III clinical trial pursuant to the revised...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Imaging Week

Source: Medical Imaging Week (2005-09-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry